Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brenipatide in Healthy Participants With Overweight or Obesity
NCT07476118Phase 1Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2026
- Primary completion
- Feb 2027
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing Brenipatide with Placebo (2 arms). Primary endpoint: Percent Change in Body Weight at Week 29. Started Mar 2026; status: active, not recruiting.
02
Drugs
brenipatide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07476118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07476118.